| Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection MS Sulkowski, DF Gardiner, M Rodriguez-Torres, KR Reddy, ... New England Journal of Medicine 370 (3), 211-221, 2014 | 1556 | 2014 |
| All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study DR Nelson, JN Cooper, JP Lalezari, E Lawitz, PJ Pockros, N Gitlin, ... Hepatology 61 (4), 1127-1135, 2015 | 892 | 2015 |
| Preliminary study of two antiviral agents for hepatitis C genotype 1 AS Lok, DF Gardiner, E Lawitz, C Martorell, GT Everson, R Ghalib, ... New England Journal of Medicine 366 (3), 216-224, 2012 | 748 | 2012 |
| Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection H Kumada, Y Suzuki, K Ikeda, J Toyota, Y Karino, K Chayama, ... Hepatology 59 (6), 2083-2091, 2014 | 662 | 2014 |
| Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence F Poordad, ER Schiff, JM Vierling, C Landis, RJ Fontana, R Yang, ... Hepatology 63 (5), 1493-1505, 2016 | 571 | 2016 |
| Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1 DL Wyles, PJ Ruane, MS Sulkowski, D Dieterich, A Luetkemeyer, ... New England Journal of Medicine 373 (8), 714-725, 2015 | 522 | 2015 |
| All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study M Manns, S Pol, IM Jacobson, P Marcellin, SC Gordon, CY Peng, ... The Lancet 384 (9954), 1597-1605, 2014 | 450 | 2014 |
| Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b … K Chayama, S Takahashi, J Toyota, Y Karino, K Ikeda, H Ishikawa, ... Hepatology 55 (3), 742-748, 2012 | 400 | 2012 |
| Hepatitis C virus drug resistance–associated substitutions: State of the art summary E Lontok, P Harrington, A Howe, T Kieffer, J Lennerstrand, O Lenz, ... Hepatology 62 (5), 1623-1632, 2015 | 342 | 2015 |
| Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY‐3+) V Leroy, P Angus, JP Bronowicki, GJ Dore, C Hezode, S Pianko, S Pol, ... Hepatology 63 (5), 1430-1441, 2016 | 339 | 2016 |
| Pegylated interferons L ambda‐1a and alfa‐2a display different gene induction and cytokine and chemokine release profiles in whole blood, human hepatocytes and peripheral blood … J Freeman, S Baglino, J Friborg, Z Kraft, T Gray, M Hill, F McPhee, ... Journal of viral hepatitis 21 (6), e1-e9, 2014 | 329 | 2014 |
| Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options Y Suzuki, K Ikeda, F Suzuki, J Toyota, Y Karino, K Chayama, Y Kawakami, ... Journal of hepatology 58 (4), 655-662, 2013 | 286 | 2013 |
| A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C … D Gardiner, J Lalezari, E Lawitz, M DiMicco, R Ghalib, KR Reddy, ... PloS one 8 (5), e63818, 2013 | 254 | 2013 |
| Efficacy of an interferon-and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection GT Everson, KD Sims, M Rodriguez-Torres, C Hézode, E Lawitz, ... Gastroenterology 146 (2), 420-429, 2014 | 234 | 2014 |
| Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032) F McPhee, AK Sheaffer, J Friborg, D Hernandez, P Falk, G Zhai, S Levine, ... Antimicrobial agents and chemotherapy 56 (10), 5387-5396, 2012 | 226 | 2012 |
| Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial S Pol, RH Ghalib, VK Rustgi, C Martorell, GT Everson, HA Tatum, ... The Lancet infectious diseases 12 (9), 671-677, 2012 | 195 | 2012 |
| Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir Y Karino, J Toyota, K Ikeda, F Suzuki, K Chayama, Y Kawakami, ... Journal of Hepatology 58 (4), 646-654, 2013 | 188 | 2013 |
| Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders AS Lok, DF Gardiner, C Hézode, EJ Lawitz, M Bourlière, GT Everson, ... Journal of hepatology 60 (3), 490-499, 2014 | 171 | 2014 |
| Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study C Hézode, GM Hirschfield, W Ghesquiere, W Sievert, M Rodriguez-Torres, ... Gut 64 (6), 948-956, 2015 | 160 | 2015 |
| Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis AJ Muir, F Poordad, J Lalezari, G Everson, GJ Dore, R Herring, A Sheikh, ... Jama 313 (17), 1736-1744, 2015 | 158 | 2015 |
